Based on it, recent research has shown that blocking CD47 could increase macrophage infiltration and sensitize NSCLC tumors to anti-angiogenic therapy, providing a novel therapic strategy for the treatment of NSCLC through disrupting of the CD47/SIRPα interaction and angiogenetic axis [232]. Here, CD47 is linked to non-small cell lung carcinoma.